Phathom Pharmaceuticals, Inc. (PHAT)
| Market Cap | 729.17M -17.4% |
| Revenue (ttm) | 239.66M +110.2% |
| Net Income | -99.07M |
| EPS | -1.27 |
| Shares Out | 79.43M |
| PE Ratio | n/a |
| Forward PE | 20.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 894,401 |
| Open | 8.89 |
| Previous Close | 8.94 |
| Day's Range | 8.78 - 9.31 |
| 52-Week Range | 8.21 - 18.31 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 21.50 (+134.21%) |
| Earnings Date | Jul 30, 2026 |
About PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros... [Read more]
Financial Performance
In 2025, Phathom Pharmaceuticals's revenue was $175.11 million, an increase of 216.93% compared to the previous year's $55.25 million. Losses were -$221.25 million, -33.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price target is $21.5, which is an increase of 134.21% from the latest price.
News
Phathom Pharmaceuticals price target lowered to $14 from $18 at Barclays
Barclays lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $14 from $18 and keeps an Overweight rating on the shares.
Phathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $20 from $22 and keeps a Buy rating on the shares following Q2 earnings. Revenue of…
Phathom Pharmaceuticals price target lowered to $21 from $28 at Raymond James
Raymond James analyst Martin Auster lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $21 from $28 and keeps a Strong Buy rating on the shares. The price target…
Phathom Pharmaceuticals price target lowered to $22 from $25 at Guggenheim
Guggenheim lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $25 and keeps a Buy rating on the shares after having updated the firm’s model to reflect…
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
Needham lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $28 and keeps a Buy rating on the shares. The company reported Q2 revenue roughly in line…
Phathom Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw 88% year-over-year revenue growth and the first positive operating profit (excl. stock comp), driven by strong VOQUEZNA prescription growth and disciplined expense management. Updated 2026 revenue guidance is $310M-$325M, with continued focus on reducing prescription friction and expanding indications.
Phathom Pharmaceuticals Earnings release: Q2 2026
Phathom Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Phathom Pharmaceuticals Quarterly report: Q2 2026
Phathom Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Phathom Pharmaceuticals Slides: Q2 2026
Phathom Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Phathom Pharmaceuticals reports Q2 non-GAAP EPS 0c, consensus (9c)
Reports Q2 revenue $74.3M, consensus $72.69M. “Q2 marked an important milestone for Phathom as we delivered strong quarterly revenue growth, achieved operating profitability, excluding stock-based com...
Phathom Pharmaceuticals lowers FY26 revenue view to $310M-$325M from $320M-$345M
FY26 revenue consensus $333.82M.
Phathom Pharmaceuticals Slides: Corporate presentation
Phathom Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroint...
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
Phathom Pharmaceuticals (PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as an investigational treatment for eosinophilic esophagi...
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 ...
Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
VOQUEZNA adoption is accelerating in GI practices, with strong prescriber and patient satisfaction, and a focus on expanding both clinical and market access confidence. Revenue is growing rapidly, profitability is expected in Q3, and a phase II EoE trial could further boost growth and exclusivity.
Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
VOQUEZNA’s rapid adoption in gastroenterology is driving strong revenue growth, with a strategic focus on high-need patients and a path to profitability this year. Physician awareness is high, and future expansion into primary care and new GI assets is planned, leveraging long-term exclusivity and a robust sales force.
Needham pharmaceuticals analysts hold analyst/industry conference call
Pharmaceuticals Analysts discuss Phathom Pharmaceuticals’s (PHAT) Voquezna (vonoprazan) on an Analyst/Industry conference call to be held on May 27.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)
Reports Q1 revenue $58.3M, consensus $56.81M. “In Q1, we more than doubled revenue compared to the prior year Q1. We have implemented our pivot to GI and the associated sales…
Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M
07:41 EDT Phathom Pharmaceuticals (PHAT) still sees 2026 revenue $320M-$34M, consensus $332.04M
Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue more than doubled year-over-year, driven by strong VOQUEZNA adoption among GI specialists and an expanded sales force. Guidance for 2026 is maintained, with operating profitability targeted by Q3 and positive cash flow in 2027.